NT5E,CD73: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of CD73,NT5E. The page also collects GeneMedi's different modalities and formats products for CD73 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the CD73 target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
The protein encoded by this gene is a plasma membrane protein that catalyzes the conversion of extracellular nucleotides to membrane-permeable nucleosides. The encoded protein is used as a determinant of lymphocyte differentiation. Defects in this gene can lead to the calcification of joints and arteries. Two transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Mar 2011]
Target ID | GM-T65116 |
Target Name | CD73 |
Gene ID | 4907 |
Gene Official Name | NT5E |
Gene Alias | CALJA, CD73, E5NT, NT, NT5, NTE, eN, eNT |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target, INN Index, Immuno-oncology Target |
Pre-made CD73-specific INN-index biosimilar (antibody&conjugates)-Oleclumab, Uliledlimab, Dresbuxelimab, Mupadolimab, dalutrafusp alfa
Anti-CD73 therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Cat No. | Products Name (INN Index) | INN Name | Previous Name | Target | Format | Order |
GMP-Bios-ab-394 | Pre-Made Oleclumab biosimilar, Whole mAb, Anti-NT5E/CD73 Antibody: Anti-NT/eN/NT5/NTE/eNT/E5NT/CALJA therapeutic antibody | Oleclumab | NT5E/CD73 | Whole mAb | ![]() | |
GMP-Bios-ab-599 | Pre-Made Uliledlimab biosimilar, Whole mAb, Anti-NT5E/CD73 Antibody: Anti-NT/eN/NT5/NTE/eNT/E5NT/CALJA therapeutic antibody | Uliledlimab | NT5E/CD73 | Whole mAb | ![]() | |
GMP-Bios-ab-660 | Pre-Made Dresbuxelimab biosimilar, Whole mAb, Anti-NT5E/CD73 Antibody: Anti-NT/eN/NT5/NTE/eNT/E5NT/CALJA therapeutic antibody | Dresbuxelimab | NT5E/CD73 | Whole mAb | ![]() | |
GMP-Bios-ab-683 | Pre-Made Mupadolimab biosimilar, Whole mAb, Anti-NT5E/CD73 Antibody: Anti-NT/eN/NT5/NTE/eNT/E5NT/CALJA therapeutic antibody | Mupadolimab | NT5E/CD73 | Whole mAb | ![]() | |
GMP-Bios-INN-793 | Pre-Made Dalutrafusp Alfa P Alfaiosimilar, Bispecific, Anti-NT5E/CD73;TGFB1;TGFB3 Antibody: Anti-eN/NTE/eNT/CALJA;CED/DPD1/IBDIMDE/LAP/TGF-beta1/TGFbeta;ARVD/ARVD1/LDS5/RNHF therapeutic antibody | dalutrafusp alfa | NT5E/CD73;TGFB1;TGFB3 | Bispecific | ![]() |
Pre-made anti-CD73 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-CD73 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-CD73 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Cat No. | Antibody Name | Format | Classified by tag | Order |
GM-Tg-hg-T65116-Ab | Anti-CD73/NT5E monoclonal antibody | mab | Biofunctional antibody, Therapeutics Target antibody | ![]() |